{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:56:22Z","timestamp":1781697382711,"version":"3.54.5"},"reference-count":57,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    With modern antiretroviral therapy (ART), HIV-1 has now become a manageable chronic condition. Among treatment-experienced (TE) people with HIV-1 (PWH), ART regimens can influence metabolic and renal outcomes and adverse events such as nausea. Regimen selection increasingly prioritizes safety, tolerability and long-term acceptability. This study compared bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) with other ART regimens in TE PWH using multilevel network meta-regression (ML-NMR), focusing on lipid profile, renal function and overall safety.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A systematic literature review (SLR) in June 2023 identified Phase III\/IV randomized controlled trials reporting safety in adult TE PWH. ML-NMR was conducted at week 48 adjusting for age, sex, race and CD4 cell count, using individual patient data from three Phase III B\/F\/TAF trials (GS-US-380-1844, -1878, -4030) and aggregate data from comparator trials.\n                    <jats:bold>Results:<\/jats:bold>\n                    At week 48, B\/F\/TAF demonstrated similar changes in total cholesterol (TC) to HDL ratio and LDL versus comparators. Compared with NNRTI (+ or \/) F\/TDF, changes in TC favored B\/F\/TAF (mean difference [MD; 95% CrI]: -12.43 [-23.26, -1.53]), but favored the NNRTI-based regimen for HDL (-4.35 [-7.76, -0.70]). Triglycerides changes favored B\/F\/TAF versus DTG\/ABC\/3TC (-15.01 [-29.18, -1.06]) and protease inhibitor (+ or \/) b + 2 NRTIs (-24.48 [-41.60, -7.47]). eGFR changes favored B\/F\/TAF versus DTG\/ABC\/3TC (3.81 [1.74, 5.97]). With some exceptions of statistical differences in both directions, B\/F\/TAF generally had similar levels of adverse events and discontinuations as other ART.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Switching to or remaining on B\/F\/TAF in TE PWH was generally well tolerated and did not worsen lipid, renal or safety outcomes versus most other contemporary ART. Improvements in select lipid parameters and stable renal function, with low rates of adverse events and discontinuation, support B\/F\/TAF as a safe option for long-term management in TE PWH.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0013","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:27:42Z","timestamp":1779971262000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative safety of B\/F\/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis"],"prefix":"10.57264","volume":"15","author":[{"given":"Tristan","family":"Curteis","sequence":"first","affiliation":[{"name":"Costello Medical, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A","family":"Eddowes","sequence":"additional","affiliation":[{"name":"Costello Medical, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Costello Medical, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Luedke","sequence":"additional","affiliation":[{"name":"Costello Medical, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Costello Medical, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Hempfling","sequence":"additional","affiliation":[{"name":"Costello Medical, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Gurney","sequence":"additional","affiliation":[{"name":"Costello Medical, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumi","family":"Gandhi-Patel","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Unger","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uche","family":"Mordi","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Chen","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jarrett","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M","family":"Sherman","sequence":"additional","affiliation":[{"name":"Nova Southeastern University, Fort Lauderdale, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Mounzer","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M","family":"Khalsa","sequence":"additional","affiliation":[{"name":"Valleywise Health McDowell Healthcare Center, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren L","family":"Dinges","sequence":"additional","affiliation":[{"name":"Seattle Infectious Disease Clinic, Seattle, WA 98101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehri S","family":"McKellar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Duke University, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Lipps","sequence":"additional","affiliation":[{"name":"Ohio State University Wexner Medical Center, Columbus, OH 43212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"8","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Adam Trickey MTM","year":"2017","unstructured":"Adam Trickey MTM, Jorg-Janne Vehreschild, Niels Obel Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 4(8), e349\u2013e356 (2017).","journal-title":"Lancet HIV"},{"issue":"5","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey A","year":"2023","unstructured":"Trickey A, Sabin CA, Burkholder G Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV 10(5), e295\u2013e307 (2023).","journal-title":"Lancet HIV"},{"issue":"9903","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks SG","year":"2013","unstructured":"Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 382(9903), 1525\u20131533 (2013).","journal-title":"Lancet"},{"issue":"7","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","article-title":"Future challenges for clinical care of an ageing population infected with HIV: a modelling study","volume":"15","author":"Smit M","year":"2015","unstructured":"Smit M, Brinkman K, Geerlings S Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect. Dis. 15(7), 810\u2013818 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"107876","DOI":"10.1016\/j.ijid.2025.107876","article-title":"Tuberculosis and HIV coinfection: progress and challenges towards reducing incidence and mortality","volume":"155","author":"Sossen B","year":"2025","unstructured":"Sossen B, Kubjane M, Meintjes G. Tuberculosis and HIV coinfection: progress and challenges towards reducing incidence and mortality. Int. J. Infect. Dis. 155, 107876 (2025).","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13643-022-02102-3","article-title":"A systematic review and meta-analysis assessing antiretroviral therapy for treatment-experienced HIV adult patients using an optimized background therapy approach: is there evidence enough for a standardized third-line strategy?","volume":"11","author":"Mocellin LP","year":"2022","unstructured":"Mocellin LP, Ziegelmann PK, Kuchenbecker R. A systematic review and meta-analysis assessing antiretroviral therapy for treatment-experienced HIV adult patients using an optimized background therapy approach: is there evidence enough for a standardized third-line strategy? Syst. Rev. 11(1), 243 (2022).","journal-title":"Syst. Rev."},{"key":"e_1_3_9_9_2","first-page":"204993612090139","article-title":"The management of treatment-experienced HIV patients (including virologic failure and switches)","volume":"7","author":"Cutrell J","year":"2020","unstructured":"Cutrell J, Jodlowski T, Bedimo R. The management of treatment-experienced HIV patients (including virologic failure and switches). Ther. Adv. Infect. Dis. 7, 2049936120901395 (2020).","journal-title":"Ther. Adv. Infect. Dis."},{"issue":"2","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/COH.0000000000000608","article-title":"Polypharmacy in HIV: recent insights and future directions","volume":"15","author":"Edelman EJ","year":"2020","unstructured":"Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Curr. Opin. HIV AIDS 15(2), 126\u2013133 (2020).","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hiv.70120","article-title":"Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025","volume":"27","author":"Ambrosioni J","year":"2026","unstructured":"Ambrosioni J, Levi LI, Alagaratnam J ; EACS Governing Board. Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025. HIV Med. 27(1), 18\u201332 (2026).","journal-title":"HIV Med."},{"issue":"11","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023","volume":"24","author":"Ambrosioni J","year":"2023","unstructured":"Ambrosioni J, Levi L, Alagaratnam J Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 24(11), 1126\u20131136 (2023).","journal-title":"HIV Med."},{"issue":"9","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1089\/aid.2018.0118","article-title":"Barriers for HIV cure: the latent reservoir","volume":"34","author":"Castro-Gonzalez S","year":"2018","unstructured":"Castro-Gonzalez S, Colomer-Lluch M, Serra-Moreno R. Barriers for HIV cure: the latent reservoir. AIDS Res. Hum. Retroviruses 34(9), 739\u2013759 (2018).","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"5","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.13446","article-title":"BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022","volume":"23","author":"Waters L","year":"2022","unstructured":"Waters L, Winston A, Reeves I BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022. HIV Med. 23(Suppl. 5), 3\u2013115 (2022).","journal-title":"HIV Med."},{"issue":"2","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/QAI.0000000000000825","article-title":"Long-term mortality in HIV-infected individuals 50 years or older: a nationwide, population-based cohort study","volume":"71","author":"Legarth RA","year":"2016","unstructured":"Legarth RA, Ahlstr\u00f6m MG, Kronborg G Long-term mortality in HIV-infected individuals 50 years or older: a nationwide, population-based cohort study. J. Acquir. Immune Defic. Syndr. 71(2), 213\u2013218 (2016).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"10107","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant J","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 390(10107), 2063\u20132072 (2017).","journal-title":"Lancet"},{"issue":"5","key":"e_1_3_9_17_2","first-page":"e25327","article-title":"Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F\/TAF or F\/TDF)","volume":"22","author":"Sax PE","year":"2019","unstructured":"Sax PE, Rockstroh J, Luetkemeyer A Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F\/TAF or F\/TDF). J. Int. AIDS Soc. 22(Suppl. 5), e25327 Abstract MOAB0105 (2019).","journal-title":"J. Int. AIDS Soc."},{"issue":"8","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"e41482","DOI":"10.1097\/MD.0000000000041482","article-title":"Efficacy and safety of switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir\/abacavir\/lamivudine: results from an open-label extension of a Phase III randomized, double-blind, multicenter, active-controlled, non-inferiority study","volume":"104","author":"Brar I","year":"2025","unstructured":"Brar I, Ruane PJ, Berhe M Efficacy and safety of switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir\/abacavir\/lamivudine: results from an open-label extension of a Phase III randomized, double-blind, multicenter, active-controlled, non-inferiority study. Medicine (Baltimore) 104(8), e41482 (2025).","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","article-title":"Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, Phase III, non-inferiority trial","volume":"5","author":"Daar ES","year":"2018","unstructured":"Daar ES, DeJesus E, Ruane P Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, Phase III, non-inferiority trial. Lancet HIV 5(7), e347\u2013e356 (2018).","journal-title":"Lancet HIV"},{"issue":"11","key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1681\/ASN.20233411S1392c","article-title":"Real-world effectiveness and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in treatment-experienced (TE) people with HIV with a history of CKD: TH-PO1072","volume":"34","author":"Rieke A","year":"2023","unstructured":"Rieke A, De Wet J, Esposito V Real-world effectiveness and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in treatment-experienced (TE) people with HIV with a history of CKD: TH-PO1072. J. Am. Soc. Nephrol. 34(Suppl. 11), 392\u2013393 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax PE","year":"2021","unstructured":"Sax PE, Rockstroh JK, Luetkemeyer AF Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin. Infect. Dis. 73(2), e485\u2013e493 (2021).","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"e_1_3_9_22_2","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, Phase IIIb, non-inferiority trial","volume":"10","author":"Ramgopal MN","year":"2023","unstructured":"Ramgopal MN, Castagna A, Cazanave C Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, Phase IIIb, non-inferiority trial. Lancet HIV 10(9), e566\u2013e577 (2023).","journal-title":"Lancet HIV"},{"key":"e_1_3_9_23_2","unstructured":"Higgins J Thomas J Chandler J Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). https:\/\/training.cochrane.org\/handbook"},{"key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).","journal-title":"BMJ"},{"issue":"1","key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"2361176","DOI":"10.1080\/25787489.2024.2361176","article-title":"Comorbidity and polypharmacy among people with HIV stratified by age, sex, and race","volume":"25","author":"Paudel M","year":"2024","unstructured":"Paudel M, Prajapati G, Buysman EK Comorbidity and polypharmacy among people with HIV stratified by age, sex, and race. HIV Res. Clin. Pract. 25(1), 2361176 (2024).","journal-title":"HIV Res. Clin. Pract."},{"issue":"12","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"e83649","DOI":"10.1371\/journal.pone.0083649","article-title":"Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study","volume":"8","author":"Cescon A","year":"2013","unstructured":"Cescon A, Patterson S, Chan K Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study. PloS One 8(12), e83649 (2013).","journal-title":"PloS One"},{"issue":"7","key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","article-title":"Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, Phase IIIb, non-inferiority trial","volume":"14","author":"Arribas JR","year":"2014","unstructured":"Arribas JR, Pialoux G, Gathe J Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, Phase IIIb, non-inferiority trial. Lancet Infect. Dis. 14(7), 581\u2013589 (2014).","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hiv.12961","article-title":"Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF\/FTC\/NNRTI to ABC\/3TC\/DTG","volume":"22","author":"Ibrahim F","year":"2021","unstructured":"Ibrahim F, Samarawickrama A, Hamzah L Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF\/FTC\/NNRTI to ABC\/3TC\/DTG. HIV Med. 22(2), 83\u201391 (2021).","journal-title":"HIV Med."},{"issue":"8","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"e73639","DOI":"10.1371\/journal.pone.0073639","article-title":"Switching tenofovir\/emtricitabine plus lopinavir\/r to raltegravir plus darunavir\/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial","volume":"8","author":"Nishijima T","year":"2013","unstructured":"Nishijima T, Gatanaga H, Shimbo T Switching tenofovir\/emtricitabine plus lopinavir\/r to raltegravir plus darunavir\/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS One 8(8), e73639 (2013).","journal-title":"PLoS One"},{"key":"e_1_3_9_30_2","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JP","year":"2019","unstructured":"Higgins JP, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. In: Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT, Thomas J, Chandler Jet al. (Eds). (2019) https:\/\/doi.org\/10.1002\/9781119536604.ch6"},{"issue":"3","key":"e_1_3_9_31_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/rssa.12579","article-title":"Multilevel network meta-regression for population-adjusted treatment comparisons","volume":"183","author":"Phillippo DM","year":"2020","unstructured":"Phillippo DM, Dias S, Ades AE Multilevel network meta-regression for population-adjusted treatment comparisons. J. R. Stat. Soc. Ser. A Stat. Soc. 183(3), 1189\u20131210 (2020).","journal-title":"J. R. Stat. Soc. Ser. A Stat. Soc."},{"key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v076.i01","article-title":"Stan: a probabilistic programming language","volume":"76","author":"Carpenter B","year":"2017","unstructured":"Carpenter B, Gelman A, Hoffman MD Stan: a probabilistic programming language. J. Stat. Software 76, 1\u201332 (2017).","journal-title":"J. Stat. Software"},{"key":"e_1_3_9_33_2","unstructured":"Phillippo DM. multinma: bayesian network meta-analysis of individual and aggregate data. R package version 0.7.0. doi: 10.5281\/zenodo.3904454 (2024). (Epub ahead of print)."},{"issue":"7","key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, Phase III, non-inferiority trial","volume":"5","author":"Molina JM","year":"2018","unstructured":"Molina JM, Ward D, Brar I Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, Phase III, non-inferiority trial. Lancet HIV 5(7), e357\u2013e365 (2018).","journal-title":"Lancet HIV"},{"issue":"5","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamacardio.2017.0264","article-title":"Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study","volume":"2","author":"Freiberg MS","year":"2017","unstructured":"Freiberg MS, Chang CH, Skanderson M Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study. JAMA Cardiol. 2(5), 536\u2013546 (2017).","journal-title":"JAMA Cardiol."},{"issue":"3","key":"e_1_3_9_36_2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/01.aids.0000327514.60879.47","article-title":"Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era","volume":"22","author":"Opravil M","year":"2008","unstructured":"Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 22(Suppl. 3), S35\u2013S40 (2008).","journal-title":"AIDS"},{"issue":"4","key":"e_1_3_9_37_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/QAI.0b013e31825c7f24","article-title":"Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system","volume":"60","author":"Chow FC","year":"2012","unstructured":"Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J. Acquir. Immune Defic. Syndr. 60(4), 351\u2013358 (2012).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"21","key":"e_1_3_9_38_2","doi-asserted-by":"crossref","first-page":"e009985","DOI":"10.1161\/JAHA.118.009985","article-title":"Adjudicated heart failure in HIV-infected and uninfected men and women","volume":"7","author":"Feinstein MJ","year":"2018","unstructured":"Feinstein MJ, Steverson AB, Ning H Adjudicated heart failure in HIV-infected and uninfected men and women. J. Am. Heart Assoc. 7(21), e009985 (2018).","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"e_1_3_9_39_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","article-title":"A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population","volume":"7","author":"Chawla A","year":"2018","unstructured":"Chawla A, Wang C, Patton C A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect. Dis. Ther. 7(2), 183\u2013195 (2018).","journal-title":"Infect. Dis. Ther."},{"issue":"1","key":"e_1_3_9_40_2","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(15)00211-8","article-title":"Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study","volume":"3","author":"Mocroft A","year":"2016","unstructured":"Mocroft A, Lundgren JD, Ross M Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV 3(1), e23\u2013e32 (2016).","journal-title":"Lancet HIV"},{"issue":"5","key":"e_1_3_9_41_2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2018.07.010","article-title":"Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analyses of results from 17 epidemiologic studies","volume":"52","author":"Dorjee K","year":"2018","unstructured":"Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analyses of results from 17 epidemiologic studies. Int. J. Antimicrob. Agents 52(5), 541\u2013553 (2018).","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"e_1_3_9_42_2","doi-asserted-by":"crossref","first-page":"ofy086","DOI":"10.1093\/ofid\/ofy086","article-title":"Abacavir use and risk for myocardial infarction and cardiovascular events: pooled analysis of data from clinical trials","volume":"5","author":"Nan C","year":"2018","unstructured":"Nan C, Shaefer M, Urbaityte R Abacavir use and risk for myocardial infarction and cardiovascular events: pooled analysis of data from clinical trials. Open Forum Infect. Dis. 5(5), ofy086 (2018).","journal-title":"Open Forum Infect. Dis."},{"issue":"4","key":"e_1_3_9_43_2","doi-asserted-by":"crossref","first-page":"ofaf177","DOI":"10.1093\/ofid\/ofaf177","article-title":"Cardiovascular hazards of abacavir- versus tenofovir-containing antiretroviral therapies: insights from an analysis of the REPRIEVE trial cohort","volume":"12","author":"Davies Smith E","year":"2025","unstructured":"Davies Smith E, Malvestutto C, Ribaudo HJ Cardiovascular hazards of abacavir- versus tenofovir-containing antiretroviral therapies: insights from an analysis of the REPRIEVE trial cohort. Open Forum Infect. Dis. 12(4), ofaf177 (2025).","journal-title":"Open Forum Infect. Dis."},{"issue":"7","key":"e_1_3_9_44_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the international antiviral society\u2013USA panel","volume":"333","author":"Gandhi RT","year":"2025","unstructured":"Gandhi RT, Landovitz RJ, Sax PE Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the international antiviral society\u2013USA panel. JAMA 333(7), 609\u2013628 (2025).","journal-title":"JAMA"},{"key":"e_1_3_9_45_2","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. (2025). Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new"},{"issue":"4","key":"e_1_3_9_46_2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","article-title":"A Phase I study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects","volume":"75","author":"Koteff J","year":"2013","unstructured":"Koteff J, Borland J, Chen S A Phase I study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br. J. Clin. Pharmacol. 75(4), 990\u2013996 (2013).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"e_1_3_9_47_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/QAD.0000000000000103","article-title":"Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity","volume":"28","author":"Yombi JC","year":"2014","unstructured":"Yombi JC, Pozniak A, Boffito M Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS 28(5), 621\u2013632 (2014).","journal-title":"AIDS"},{"issue":"2","key":"e_1_3_9_48_2","doi-asserted-by":"crossref","first-page":"e86311","DOI":"10.1371\/journal.pone.0086311","article-title":"Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infection","volume":"9","author":"Margolick JB","year":"2014","unstructured":"Margolick JB, Jacobson LP, Schwartz GJ Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infection. PloS One 9(2), e86311 (2014).","journal-title":"PloS One"},{"issue":"2","key":"e_1_3_9_49_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/hiv.13721","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis","volume":"26","author":"Eron JJ","year":"2025","unstructured":"Eron JJ, Ramgopal M, Osiyemi O Bictegravir\/emtricitabine\/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis. HIV Med. 26(2), 302\u2013307 (2025).","journal-title":"HIV Med."},{"issue":"1","key":"e_1_3_9_50_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clinthera.2018.11.002","article-title":"Drug discontinuation in studies including a switch from an originator to a biosimilar monoclonal antibody: a systematic literature review","volume":"41","author":"Bakalos G","year":"2019","unstructured":"Bakalos G, Zintzaras E. Drug discontinuation in studies including a switch from an originator to a biosimilar monoclonal antibody: a systematic literature review. Clin. Therapeut. 41(1), 155\u2013173.e113 (2019).","journal-title":"Clin. Therapeut."},{"issue":"20","key":"e_1_3_9_51_2","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1002\/cam4.3335","article-title":"Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials","volume":"9","author":"Mouillet GA-O","year":"2020","unstructured":"Mouillet GA-O, Efficace FA-O, Thiery-Vuillemin A Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials. Cancer Med. 9(20), 7363\u20137374 (2020).","journal-title":"Cancer Med."},{"issue":"10","key":"e_1_3_9_52_2","doi-asserted-by":"crossref","first-page":"ofae560","DOI":"10.1093\/ofid\/ofae560","article-title":"Efficacy, safety, and tolerability of switching from bictegravir\/emtricitabine\/tenofovir alafenamide to dolutegravir\/lamivudine among adults with virologically suppressed HIV: the DYAD study","volume":"11","author":"Rolle CA-O","year":"2024","unstructured":"Rolle CA-O, Castano J, Nguyen V, Hinestrosa FA-O, DeJesus E. Efficacy, safety, and tolerability of switching from bictegravir\/emtricitabine\/tenofovir alafenamide to dolutegravir\/lamivudine among adults with virologically suppressed HIV: the DYAD study. Open Forum Infect. Dis. 11(10), ofae560 (2024).","journal-title":"Open Forum Infect. Dis."},{"issue":"6","key":"e_1_3_9_53_2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the Phase III, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi O","year":"2022","unstructured":"Osiyemi O, De Wit S, Ajana F Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the Phase III, noninferiority TANGO randomized trial. Clin. Infect. Dis. 75(6), 975\u2013986 (2022).","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"e_1_3_9_54_2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the Phase III, noninferiority SALSA randomized Trial","volume":"76","author":"Llibre JM","year":"2023","unstructured":"Llibre JM, Brites C, Cheng CY Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the Phase III, noninferiority SALSA randomized Trial. Clin. Infect. Dis. 76(4), 720\u2013729 (2023).","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"e_1_3_9_55_2","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, Phase III SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud M","year":"2019","unstructured":"Aboud M, Orkin C, Podzamczer D Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, Phase III SWORD-1 and SWORD-2 studies. Lancet HIV 6(9), e576\u2013e587 (2019).","journal-title":"Lancet HIV"},{"issue":"7","key":"e_1_3_9_56_2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1473-3099(14)70796-0","article-title":"Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, Phase IIIb non-inferiority trial","volume":"14","author":"Pozniak A","year":"2014","unstructured":"Pozniak A, Markowitz M, Mills A Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, Phase IIIb non-inferiority trial. Lancet Infect. Dis. 14(7), 590\u2013599 (2014).","journal-title":"Lancet Infect. Dis."},{"issue":"11","key":"e_1_3_9_57_2","doi-asserted-by":"crossref","first-page":"e112836","DOI":"10.1371\/journal.pone.0112836","article-title":"Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study","volume":"9","author":"Lafaurie M","year":"2014","unstructured":"Lafaurie M, De Sousa B, Ponscarme D Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study. PLoS One 9(11), e112836 (2014).","journal-title":"PLoS One"},{"issue":"4","key":"e_1_3_9_58_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/QAI.0b013e318221863f","article-title":"Effect of nonnucleoside reverse transcriptase inhibitor\u2013based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients","volume":"57","author":"Dave JA","year":"2011","unstructured":"Dave JA, Lambert EV, Badri M, West S, Maartens G, Levitt NS. Effect of nonnucleoside reverse transcriptase inhibitor\u2013based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J. Acquir. Immune Defic. Syndr. 57(4), 284\u2013289 (2011).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"e_1_3_9_59_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1310\/F2V7-3R46-VX6J-241R","article-title":"Lipid changes in patients initiating efavirenz-and indinavir-based antiretroviral regimens","volume":"4","author":"Karen TT","year":"2003","unstructured":"Karen TT, Linda B, Elizabeth A, Esther A, Timothy PF. Lipid changes in patients initiating efavirenz-and indinavir-based antiretroviral regimens. HIV Clin. Trials 4(1), 29\u201336 (2003).","journal-title":"HIV Clin. Trials"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:21:30Z","timestamp":1781695290000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.57264\/cer-2026-0013"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0013","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e260013"}}